GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Plus Therapeutics Inc (NAS:PSTV) » Definitions » Shiller PE Ratio

Plus Therapeutics (Plus Therapeutics) Shiller PE Ratio : (As of Apr. 27, 2024)


View and export this data going back to 2000. Start your Free Trial

What is Plus Therapeutics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Plus Therapeutics Shiller PE Ratio Historical Data

The historical data trend for Plus Therapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Plus Therapeutics Shiller PE Ratio Chart

Plus Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Plus Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Plus Therapeutics's Shiller PE Ratio

For the Biotechnology subindustry, Plus Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Plus Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Plus Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Plus Therapeutics's Shiller PE Ratio falls into.



Plus Therapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Plus Therapeutics's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, Plus Therapeutics's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.7/129.4194*129.4194
=-0.700

Current CPI (Dec. 2023) = 129.4194.

Plus Therapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201403 -14,772.700 99.695 -19,177.326
201406 -15,940.700 100.560 -20,515.574
201409 -12,032.100 100.428 -15,505.539
201412 -7,470.330 99.070 -9,758.843
201503 -21,238.500 99.621 -27,591.283
201506 3,375.000 100.684 4,338.236
201509 1,125.000 100.392 1,450.290
201512 -2,142.280 99.792 -2,778.294
201603 -3,075.000 100.470 -3,961.014
201606 -3,225.000 101.688 -4,104.488
201609 -1,950.000 101.861 -2,477.571
201612 -1,800.000 101.863 -2,286.950
201703 -2,475.000 102.862 -3,114.001
201706 -1,455.000 103.349 -1,822.031
201709 -1,042.500 104.136 -1,295.616
201712 -1,507.500 104.011 -1,875.759
201803 -547.500 105.290 -672.974
201806 -442.500 106.317 -538.655
201809 -414.450 106.507 -503.610
201812 -113.083 105.998 -138.070
201903 -133.800 107.251 -161.457
201906 -310.050 108.070 -371.303
201909 -0.450 108.329 -0.538
201912 3.417 108.420 4.079
202003 -4.200 108.902 -4.991
202006 -6.750 108.767 -8.032
202009 -5.850 109.815 -6.894
202012 -10.950 109.897 -12.895
202103 -4.950 111.754 -5.732
202106 -3.750 114.631 -4.234
202109 -4.200 115.734 -4.697
202112 -4.050 117.630 -4.456
202203 -2.850 121.301 -3.041
202206 -3.560 125.017 -3.685
202209 -2.850 125.227 -2.945
202212 -2.360 125.222 -2.439
202303 -2.100 127.348 -2.134
202306 -0.590 128.729 -0.593
202309 -1.000 129.860 -0.997
202312 -0.700 129.419 -0.700

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Plus Therapeutics  (NAS:PSTV) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Plus Therapeutics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Plus Therapeutics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Plus Therapeutics (Plus Therapeutics) Business Description

Traded in Other Exchanges
Address
4200 Marathon Boulevard, Suite 200, Austin, TX, USA, 78756
Plus Therapeutics Inc is a clinical-stage pharmaceutical company. The company focused on the discovery, development, and delivery of complex and innovative treatments for patients battling cancer and rare diseases. Its product pipeline includes Patented RNL and Patented DocePLUS.
Executives
Marc H Hedrick officer: President C/O CYTORI THERAPEUTICS, INC., 3020 CALLAN ROAD, SAN DIEGO CA 92121
Robert P Lenk director LUNA INNOVATIONS INCORPORATED, 2851 COMMERCE STREET, BLACKSBURG VA 24060
Howard Clowes director 217 DWIGHT ROAD, BURLINGAME CA 94010
Greg Petersen director 3100 MAIN STREET, SUITE 900, HOUSTON TX 77002
Sims Andrew John Hugh Macintyre officer: Chief Financial Officer 4200 MARATHON BOULEVARD, SUITE 200, AUSTIN TX 78756
Norman D. Lafrance officer: CHIEF MEDICAL OFFICER MOLECULAR INSIGHT PHARMCEUTICALS, INC., 160 SECOND STREET, CAMBRIDGE MA 02142
Es-johansson An Van director 6863 BEE CAVE ROAD, SUITE 200, AUSTIN TX 78736
Ag Postfinance 10 percent owner MINGERSTRASSE 20, BERN V8 3030
Bank Sa Swissquote 10 percent owner CHEMIN DE LA CRETAUX 33, GLAND V8 1196
Anthony Gregg Lapointe director PO BOX 83216, GAITHERSBURG MD 20883-3216
Ron Martell director PONIARD PHARMACEUTICALS, INC., 750 BATTERY STREET, SUITE 330, SAN FRANCISCO CA 94111
Mark Marino officer: Chief Medical Officer C/O CYTORI THERAPEUTICS, INC., 3020 CALLAN ROAD, SAN DIEGO CA 92121
John David Harris officer: VP and GM of Cell Therapy 3020 CALLAN ROAD, SAN DIEGO CA 92121
Gail K Naughton director C. R. BARD, INC., 730 CENTRAL AVENUE, MURRAY HILL NJ 07974
David Rickey director